224 related articles for article (PubMed ID: 32933947)
21. Histologic Features Do Not Reliably Predict Mismatch Repair Protein Deficiency in Colorectal Carcinoma: The Results of a 5-Year Prospective Evaluation.
Olevian DC; Pai RK
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):231-238. PubMed ID: 29189259
[TBL] [Abstract][Full Text] [Related]
22. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome.
Poulogiannis G; Frayling IM; Arends MJ
Histopathology; 2010 Jan; 56(2):167-79. PubMed ID: 20102395
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
24. Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies.
Ryan NAJ; Walker TDJ; Bolton J; Ter Haar N; Van Wezel T; Glaire MA; Church DN; Evans DG; Bosse T; Crosbie EJ
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572765
[TBL] [Abstract][Full Text] [Related]
25. Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L; Hollebecque A; Yurchenko AA; de Forceville L; Danjou M; Jouniaux JM; Rosa RCA; Pouvelle C; Aoufouchi S; Vuagnat P; Smolenschi C; Colomba E; Leary A; Marabelle A; Scoazec JY; Cassard L; Nikolaev S; Chaput N; Kannouche P
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35896284
[TBL] [Abstract][Full Text] [Related]
26. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
Kim SR; Tone A; Kim R; Cesari M; Clarke B; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
Int J Gynecol Cancer; 2020 Dec; 30(12):1951-1958. PubMed ID: 33082239
[TBL] [Abstract][Full Text] [Related]
27. Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma.
Perna C; Navarro A; Ruz-Caracuel I; Caniego-Casas T; Cristóbal E; Leskelä S; Longo F; Caminoa A; Santón A; Ferreiro R; Pizarro D; Palacios-Berraquero ML; Palacios J
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435234
[TBL] [Abstract][Full Text] [Related]
28. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
29. Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.
Chow RD; Michaels T; Bellone S; Hartwich TMP; Bonazzoli E; Iwasaki A; Song E; Santin AD
Cancer Discov; 2023 Feb; 13(2):312-331. PubMed ID: 36301137
[TBL] [Abstract][Full Text] [Related]
30. [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation].
Czakó L; Tiszlavicz L; Takács R; Baradnay G; Lonovics J; Cserni G; Závodná K; Bartosova Z
Orv Hetil; 2005 May; 146(20):1009-16. PubMed ID: 15945244
[TBL] [Abstract][Full Text] [Related]
31. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
[TBL] [Abstract][Full Text] [Related]
32. Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations.
Egoavil CM; Montenegro P; Soto JL; Casanova L; Sanchez-Lihon J; Castillejo MI; Martinez-Canto A; Perez-Carbonell L; Castillejo A; Guarinos C; Barbera VM; Jover R; Paya A; Alenda C
Pathology; 2011 Apr; 43(3):228-33. PubMed ID: 21436632
[TBL] [Abstract][Full Text] [Related]
33. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
34. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency.
Jensen LH; Lindebjerg J; Byriel L; Kolvraa S; Crüger DG
Colorectal Dis; 2008 Jun; 10(5):490-7. PubMed ID: 17868408
[TBL] [Abstract][Full Text] [Related]
35. Frequency of immunohistochemical loss of mismatch repair protein in double primary cancers of the colorectum and stomach in Japan.
Hayashi T; Arai M; Ueno M; Kinoshita H; Tada Y; Koizumi K; Miki Y; Yamaguchi T; Kato Y; Utsunomiya J; Muto T; Sugihara K
Dis Colon Rectum; 2006 Oct; 49(10 Suppl):S23-9. PubMed ID: 17106811
[TBL] [Abstract][Full Text] [Related]
36. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
38. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
39. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
[TBL] [Abstract][Full Text] [Related]
40. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
